Your browser doesn't support javascript.
loading
The Uncomplicated Course of COVID-19 in Primary Immunodeficiency Patients: A Report of 14 Common Variable Immunodeficiency Patients.
Nabavi, Mohammad; Mohammadi, Faezeh; Arshi, Saba; Bemanian, Mohammad Hasan; Fallahpour, Morteza; Atashrazm, Fatemeh; Shokri, Sima.
Afiliación
  • Nabavi M; Department of Allergy and Clinical Immunology, Rasool e Akram Hospital, Iran University of Medical Sciences, Tehran, Iran. Mnabavi44@yahoo.com.
  • Mohammadi F; School of Medicine, Iran University of Medical Sciences, Tehran, Iran. faezehmohammadi96@gmail.com.
  • Arshi S; Department of Allergy and Clinical Immunology, Rasool e Akram Hospital, Iran University of Medical Sciences, Tehran, Iran. Sabaarshi@yahoo.com.
  • Bemanian MH; Department of Allergy and Clinical Immunology, Rasool e Akram Hospital, Iran University of Medical Sciences, Tehran, Iran. Mhbemanian@yahoo.com.
  • Fallahpour M; Department of Allergy and Clinical Immunology, Rasool e Akram Hospital, Iran University of Medical Sciences, Tehran, Iran. Fallahpour.morteza@yahoo.com.
  • Atashrazm F; Department of Allergy and Clinical Immunology, Rasool e Akram Hospital, Iran University of Medical Sciences, Tehran, Iran. dr.atashrazm@gmail.com.
  • Shokri S; Department of Allergy and Clinical Immunology, Rasool e Akram Hospital, Iran University of Medical Sciences, Tehran, Iran. dr.shokri.83@gmail.com.
Iran J Allergy Asthma Immunol ; 21(5): 594-599, 2022 Oct 26.
Article en En | MEDLINE | ID: mdl-36341567
ABSTRACT
Coronavirus disease 2019 (COVID-19) affects millions of people worldwide. Clinical manifestations range from asymptomatic to severe viral pneumonia. CVID patients with COVID-19 infection are not adequately studied. In some studies, CVID patients had higher mortality rates, although other studies showed that CVID patients might have an uncomplicated COVID-19 infection. We describe 14 cases of COVID-19 infection in Iranian CVID patients in this study, including clinical manifestations, laboratory findings, and treatment strategies. There were 29% of patients with mild disease, 43% with moderate disease, and 29% with severe disease in this study. A critical case and a death occurred in none of our patients. There were six cases of infection more than two weeks after receiving the second dose of Sinopharm BIBP COVID-19 vaccine; all had mild to moderate disease. Among these patients, Remdesivir was the most frequently prescribed medication. According to this study, most of our patients presented with an uncomplicated disease course.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neumonía Viral / Inmunodeficiencia Variable Común / COVID-19 Tipo de estudio: Diagnostic_studies Límite: Humans País/Región como asunto: Asia Idioma: En Revista: Iran J Allergy Asthma Immunol Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2022 Tipo del documento: Article País de afiliación: Irán

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neumonía Viral / Inmunodeficiencia Variable Común / COVID-19 Tipo de estudio: Diagnostic_studies Límite: Humans País/Región como asunto: Asia Idioma: En Revista: Iran J Allergy Asthma Immunol Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2022 Tipo del documento: Article País de afiliación: Irán